These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 17373267)

  • 1. [How to analyze and prevent the risks associated with the use of erythropoiesis stimulating agents].
    Dussert S; Ferrandini C; Hurot JM; Magnam J; Ortiz JP
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S256-60. PubMed ID: 17373267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprex-associated pure red cell aplasia and leachates.
    Schellekens H; Jiskoot W
    Nat Biotechnol; 2006 Jun; 24(6):613-4. PubMed ID: 16763579
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin (Procrit; Epogen) revisited.
    Med Lett Drugs Ther; 2001 May; 43(1104):40-1. PubMed ID: 11353925
    [No Abstract]   [Full Text] [Related]  

  • 14. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
    Locatelli F; Gascón P
    Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
    Carrera F; Disney A; Molina M
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemoglobin variability in patients with chronic renal insuffiency].
    Deray G
    Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit.
    Dharmarajan TS; Widjaja D
    Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.